Last reviewed · How we verify

Tramadol with ropivacaine

Aristotle University Of Thessaloniki · FDA-approved active Small molecule

Tramadol with ropivacaine is a Opioid analgesic combined with local anesthetic Small molecule drug developed by Aristotle University Of Thessaloniki. It is currently FDA-approved for Acute and chronic pain management, Perioperative and postoperative pain control. Also known as: TR.

Tramadol provides systemic opioid analgesia while ropivacaine delivers local anesthetic blockade of nerve conduction at the site of administration.

Tramadol provides systemic opioid analgesia while ropivacaine delivers local anesthetic blockade of nerve conduction at the site of administration. Used for Acute and chronic pain management, Perioperative and postoperative pain control.

At a glance

Generic nameTramadol with ropivacaine
Also known asTR
SponsorAristotle University Of Thessaloniki
Drug classOpioid analgesic combined with local anesthetic
TargetMu-opioid receptor (tramadol); voltage-gated sodium channels (ropivacaine)
ModalitySmall molecule
Therapeutic areaPain management
PhaseFDA-approved

Mechanism of action

Tramadol is a centrally-acting synthetic opioid that inhibits reuptake of norepinephrine and serotonin while acting as a weak mu-opioid receptor agonist, producing systemic pain relief. Ropivacaine is a local anesthetic that blocks sodium channels in nerve membranes, preventing action potential propagation and producing regional anesthesia. The combination provides both systemic and local pain control.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Tramadol with ropivacaine

What is Tramadol with ropivacaine?

Tramadol with ropivacaine is a Opioid analgesic combined with local anesthetic drug developed by Aristotle University Of Thessaloniki, indicated for Acute and chronic pain management, Perioperative and postoperative pain control.

How does Tramadol with ropivacaine work?

Tramadol provides systemic opioid analgesia while ropivacaine delivers local anesthetic blockade of nerve conduction at the site of administration.

What is Tramadol with ropivacaine used for?

Tramadol with ropivacaine is indicated for Acute and chronic pain management, Perioperative and postoperative pain control.

Who makes Tramadol with ropivacaine?

Tramadol with ropivacaine is developed and marketed by Aristotle University Of Thessaloniki (see full Aristotle University Of Thessaloniki pipeline at /company/aristotle-university-of-thessaloniki).

Is Tramadol with ropivacaine also known as anything else?

Tramadol with ropivacaine is also known as TR.

What drug class is Tramadol with ropivacaine in?

Tramadol with ropivacaine belongs to the Opioid analgesic combined with local anesthetic class. See all Opioid analgesic combined with local anesthetic drugs at /class/opioid-analgesic-combined-with-local-anesthetic.

What development phase is Tramadol with ropivacaine in?

Tramadol with ropivacaine is FDA-approved (marketed).

What are the side effects of Tramadol with ropivacaine?

Common side effects of Tramadol with ropivacaine include Nausea, Dizziness, Constipation, Local injection site reactions, Headache.

What does Tramadol with ropivacaine target?

Tramadol with ropivacaine targets Mu-opioid receptor (tramadol); voltage-gated sodium channels (ropivacaine) and is a Opioid analgesic combined with local anesthetic.

Related